Avtor/Urednik		Gradišnik, Suzana; Krajnc, Ivan
Naslov		Mehanizmi delovanja novih imunomodulirajočih zdravil za zdravljenje revmatoidnega artritisa
Prevedeni naslov		Mechanisms of action of novel immunomodulating drugs in the management of rheumatoid arthritis
Tip		članek
Vir		In: Hojs R, Krajnc I, Pahor A, et al, editors. Zbornik predavanj in praktikum Iz prakse za prakso z mednarodno udeležbo. 13. srečanje internistov in zdravnikov splošne medicine; 2002 maj 10-11; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje		2002
Obseg		str. 73-81
Jezik		slo
Abstrakt		Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology. Agents that target cells and molecules involved in chronic inflammation are coming in use for the treatment of RA. Proliferation of autoimmune T lymphocytes can be arrested by leflunomide, an immunomodulating drug exerting its effects by inhibiting the mitochondrial enzyme dihydroorotate-dehydrogenase (DHODH), which plays a key role in the de novo ribonucleotide synthesis. Among the many cytokines involved in RA tumour necrosis factor alpha (TNF-alpha ) is believed to be crucial. Two agents for neutralizing TNF-alpha are available now: etanercept, a recombinant molecule, which is derived from a naturally occurring TNF-alpha antagonist, and infliximab, alpha chimeric monoclonal antibody against human TNF-alpha.
Deskriptorji		ARTHRITIS, RHEUMATOID ADJUVANTS, IMMUNOLOGIC TUMOR NECROSIS FACTOR RECEPTORS, INTERLEUKIN-2 RECEPTORS, ANTIGEN, T-CELL